<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01022970</url>
  </required_header>
  <id_info>
    <org_study_id>CQAX576A2205</org_study_id>
    <nct_id>NCT01022970</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis</brief_title>
  <official_title>A Double Blinded Randomized Placebo-controlled Trial of Intravenous QAX576 in the Treatment of Eosinophilic Esophagitis (EoE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study is designed to investigate the effects of a 12 week course of intravenous QAX576
      6mg/kg every 4 weeks in reducing the number of eosinophils in the esophagus of EoE patients
      by 75% or greater when compared with baseline.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint in this study is the number of patients (responder) with a reduction of 75% or more in eosinophils per HPF (distal or proximal esophagus) from baseline to week 13.</measure>
    <time_frame>13 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To ascertain the effect of QAX576 in the frequency and severity of the symptoms of EoE.</measure>
    <time_frame>34 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate the safety and tolerability of QAX576 in patients with EoE.</measure>
    <time_frame>34 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To establish the duration of clinical benefit after a 12 week course of therapy.</measure>
    <time_frame>34 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK/PD relationship between blood levels of QAX576 and IL- 13 dependent gene expression in esophageal biopsies and soluble biomarkers, inflammatory and fibrotic markers within esophageal biopsies and activation markers expressed on peripheral</measure>
    <time_frame>34 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Eosinophilic Esophagitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>QAX576</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QAX576 placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QAX576</intervention_name>
    <arm_group_label>QAX576</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females aged 18-50 with symptomatic eosinophilic esophagitis

          -  Female subjects must be women of non child bearing potential.

          -  Elimination diet must have been tried.

          -  Treatment for at least two months prior to enrollment on a protocol pump inhibitor .

          -  Appropriate contraception must be used by males, (e.g., spermicidal gel plus condom)

          -  Must be able to communicate well with the investigator, to understand and comply with
             the requirements of the study.

          -  Understand and sign the written informed consent.

        Exclusion criteria:

          -  Have received corticosteroids within 3 months before starting the study for any
             symptoms.

          -  Any other eosinophilic disorders.

          -  History of clinical schistosomiasis, or having travelled within the preceding 6 months
             to an area with endemic schistosomiasis, including but not limited to Southeast and
             Southwest Asia, South America and Africa. Travel to these areas must not be planned
             for at least 6 months after the last dose.

          -  Donation or loss of 400 ml or more of blood within eight (8) weeks prior to initial
             dosing.

          -  History of immunodeficiency diseases, including a positive HIV (ELISA and Western
             blot) test result.

          -  History of drug or alcohol abuse within the 12 months prior to dosing, or evidence of
             such abuse as indicated by the laboratory assays conducted during the screening.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stanford Medical Center and Lucile Packard Children's Hospital</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Minnesota</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oral Alpan, 6210 Old Keene Mill Court,</name>
      <address>
        <city>Springfield</city>
        <state>Virginia</state>
        <zip>22152</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2009</study_first_submitted>
  <study_first_submitted_qc>November 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2009</study_first_posted>
  <disposition_first_submitted>October 29, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>October 29, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 21, 2013</disposition_first_posted>
  <last_update_submitted>November 21, 2013</last_update_submitted>
  <last_update_submitted_qc>November 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Esophagitis</keyword>
  <keyword>Digestive System Diseases</keyword>
  <keyword>Esophageal disorder</keyword>
  <keyword>Eosinophilic esophagitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Eosinophilic Esophagitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

